Data sharing more efficient with purpose-built LIMS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Data sharing more efficient with purpose-built LIMS
A laboratory information system (LIMS) is a key tool in facilitating communication between a pharmaceutical company and its outsourcing partners; however, most LIMS require extensive customisation before they can be used in the pharmaceutical industry. In comparison, purpose-built LIMS offering pharma-specific functionality out-of-the-box can reduce validation and deployment times, and enable real-time information sharing.


Pharmaceutical Technology Europe
Volume 22, Issue 6


(KICK IMAGES/GETTY IMAGES)
The pressure to contain costs is at an all time high for the pharma industry as the cost of raw materials continues to rise and more stringent regulatory requirements are mandated. In response, the industry is increasingly outsourcing manufacturing operations and raw materials development, which has led to a growth in the number of CMOs and API manufacturers. Just as pharma companies must comply with the FDA and other regulations, however, outsourced suppliers must also provide the same level of compliance throughout the entire process or production line. Furthermore, they must show their pharma sponsors the transparency necessary to obtain data quickly and easily.

As the sponsor pharmaceutical company is ultimately responsible for the quality and safety of the developed drug, it will often dictate to CMOs and API manufacturers which methods and processes will be used. The sponsor will also usually deploy informatics software that facilitates information sharing and enables a reliable audit trail of data management to be traced through product development and manufacture. Enterprise level laboratory information management systems (LIMS) are increasingly relied upon as key contributors in this effort. Delivering advanced functionality that is specific to each stage of the drug development process, sophisticated and purposebuilt LIMS streamline processes, automate operations and reduce costs. The systems deliver real-time analysis and reports, facilitating regulatory compliance and product quality, and can integrate with a company's broader network to provide secure access to key data throughout the organisation.

Not all LIMS are created equal

Historically, industry standard LIMS have only delivered 30–40% of specific functionality targeted to each user's needs and have required extensive customisation to make them function in that particular setting.1 This minimal industryspecific functionality, combined with often outofdate proprietary languages or reliance on a costly IT infrastructure, has been particularly troublesome in the pharmaceutical industry, which has traditionally relied upon its own user documentation, design documentation, validation scripts and help files — all of which require continuous maintenance by an extensive IT staff. This high degree of customisation presents a drain on resources and increases the expense associated with maintaining laboratory infrastructure. As a consequence, implementing LIMS in various pharmaceutical laboratory settings has typically been a long, costly and arduous process — not only during installation and validation, but also in operating and maintaining the system over time.

The growing mandates of global regulatory compliance and longterm data traceability, as well as the complexity of laboratory testing and emphasis on batch versus sample management, have forced pharmaceutical manufacturers to extensively adapt generic LIMS to meet their specific requirements — lengthy and costly customisation, validation and implementation periods (in many cases lasting 36 months or more) have become routine.1

Because pharmaceutical companies rely on the external services of CMOs for production and API manufacturers for their raw materials, it is advantageous for informatics systems to be aligned between the sponsoring pharma company and their outsourced partners. This ensures that processes are consistent, manufacturing protocols are reliably maintained and that data are available throughout the entire chain of production to all levels of management in the sponsoring company.

Purpose-built LIMS

Purpose-built LIMS that provide as much application-specific functionality as possible outofthebox eliminate the need for customisation and, ultimately, result in reduced validation and deployment time, as well as easier ongoing support. Such systems are already being implemented by many pharmaceutical companies because they provide the necessary documentation to meet regulatory and government standards, and can also help to generate cost savings in personnel and production time.

Purpose-built LIMS for pharmaceutical manufacturing processes have a unique batch and product-oriented design that aligns directly with the manufacturing workflow, allowing production data to be logically organised, summarised and reported. The system can also incorporate dashboardready functionality, enabling managers to make faster, more informed decisions. Further, if the system is built on Microsoft compatible interfaces, this can help facilitate end-user acceptance and support for the process modifications. A key component of any purposebuilt LIMS for pharmaceutical manufacturing should also be an environmental monitoring module that helps improve product quality monitoring and aid compliance by documenting important parts of the process and the environmental conditions involved. Additional standard functionality should also include dissolution and stability testing functionality, as well as product and batch management that provides laboratory managers with more control over their processes and more electronicallygenerated information for audit trail purposes.

The builtin functionalities as described above enable more real-time information sharing between the pharmaceutical sponsor and its external suppliers, and also enable faster and more streamlined decision making — with an effective LIMS in place at all points of manufacturing, pharma sponsors have the information they need at each critical point in the production chain. According to a recent industry report,1 LIMS customers are looking for more "outofthebox" functionality, and expect LIMS to deliver the associated time and cost savings this specific functionality will bring.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here